Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study
dc.contributor.author | Pivonello, Rosario | |
dc.contributor.author | Bancos, Irina | |
dc.contributor.author | Feelders, Richard A. | |
dc.contributor.author | Kargi, Atil Y. | |
dc.contributor.author | Kerr, Janice M. | |
dc.contributor.author | Gordon, Murray B. | |
dc.contributor.author | Mariash, Cary N. | |
dc.contributor.author | Terzolo, Massimo | |
dc.contributor.author | Ellison, Noel | |
dc.contributor.author | Moraitis, Andreas G. | |
dc.contributor.department | Medicine, School of Medicine | en_US |
dc.date.accessioned | 2023-06-26T17:20:39Z | |
dc.date.available | 2023-06-26T17:20:39Z | |
dc.date.issued | 2022-04-27 | |
dc.description.abstract | [This corrects the article DOI: 10.3389/fendo.2021.662865.]. | en_US |
dc.eprint.version | Final published version | en_US |
dc.identifier.citation | Pivonello R, Bancos I, Feelders RA, et al. Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study. Front Endocrinol (Lausanne). 2022;13:899616. Published 2022 Apr 27. doi:10.3389/fendo.2022.899616 | en_US |
dc.identifier.uri | https://hdl.handle.net/1805/33972 | |
dc.language.iso | en_US | en_US |
dc.publisher | Frontiers Media | en_US |
dc.relation.isversionof | 10.3389/fendo.2022.899616 | en_US |
dc.relation.journal | Frontiers in Endocrinology | en_US |
dc.rights | Attribution 4.0 International | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | * |
dc.source | PMC | en_US |
dc.subject | Cushing syndrome | en_US |
dc.subject | Clinical trial | en_US |
dc.subject | Cortisol | en_US |
dc.subject | Glucocorticoid | en_US |
dc.subject | Hypercortisolism | en_US |
dc.subject | Hyperglycemia | en_US |
dc.subject | Hypertension | en_US |
dc.subject | Relacorilant | en_US |
dc.title | Corrigendum: Relacorilant, a Selective Glucocorticoid Receptor Modulator, Induces Clinical Improvements in Patients With Cushing Syndrome: Results From A Prospective, Open-Label Phase 2 Study | en_US |
dc.type | Article | en_US |